Brief: Mabpharm Says Unit Granted Kexing Bioproducts An Exclusive License For Development Of An Antibody
29/06/2021 16:30
June 29 (Reuters) - Mabpharm Ltd 2181.HK :
* UNIT GRANTED KEXING BIOPRODUCTS AN EXCLUSIVE LICENSE FOR
DEVELOPMENT & COMMERCIALIZATION OF CMAB008, AN ANTIBODY
Source text for Eikon: ID:nHKSbrwhTj
Further company coverage: 2181.HK
((reuters.briefs@thomsonreuters.com))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008